METHOD OF TREATING COVID-19 USING OX40 (CD134) RECEPTOR AGONISTS Russian patent published in 2024 - IPC A61K39/395 A61P37/00 

FIELD: medicine; pharmaceutics.

SUBSTANCE: invention relates to the field of medicine and pharmaceutics, namely to the use of a drug acting on CD8+ T-lymphocytes of memory for coronavirus infections preceding infection with coronavirus SARS-CoV-2, in an individual, wherein said CD8+ T-lymphocytes are activated in said individual when infected with coronavirus SARS-CoV-2, for correction of inadequate immune response to infection with coronavirus SARS-CoV-2, in said individual or to generate an adequate immune response to said infection in said individual. Use of a drug acting on CD8+ T-lymphocytes of memory for coronavirus infections preceding infection with coronavirus SARS-CoV-2, in an individual, where said CD8+ T-lymphocytes are activated in said individual when infected with coronavirus SARS-CoV-2, to correct an inadequate immune response to infection with coronavirus SARS-CoV-2, in said individual or to generate an adequate immune response to said infection in said individual, where the effect on CD8+ T-lymphocytes of memory to coronavirus infections preceding infection with coronavirus SARS-CoV-2 in an individual, activated in said individual when infected with coronavirus SARS-CoV-2, includes one of the following: stimulating these lymphocytes and increasing their activity with respect to SARS-CoV-2 antigens; reduced level of apoptosis of these lymphocytes; reducing the level of death of these lymphocytes; inducing an increase in the activity of these lymphocytes with respect to SARS-CoV-2 antigens; increased migration of these lymphocytes to the source of antigen production, i.e. to tissues affected by SARS-CoV-2 virus; reduced ability of these lymphocytes to activate apoptosis in lymphocytes highly avid to SARS-CoV-2 virus; reduced ability of these lymphocytes to initiate death of lymphocytes highly avid to SARS-CoV-2 virus; stimulating the destruction of cells affected by the SARS-CoV-2 virus; high efficiency of eliminating the SARS-CoV-2 virus, where the inadequate immune response is the immune response, which is caused by or consists in stimulation of CD8+ T-lymphocyte proliferation in this individual to previous coronaviruses, characterized by reduced avidity to coronavirus SARS-CoV-2, high level of intrinsic apoptosis and stimulating activity on high avid CD8+ T-lymphocytes.

EFFECT: said invention enables to restore functional activity of CD8+ T-lymphocytes of memory to previous coronavirus infections, characterized by reduced avidity to antigens SARS-CoV-2, with respect to antigens of said virus, represented by cells affected by the virus, suppress the individual’s inadequate immune response during infection with SARS-CoV-2, caused by activation of proliferation of CD8+ T-lymphocytes of memory to previous coronavirus infections during infection with SARS-CoV-2 in an individual and manifested by increased apoptosis and death of such lymphocytes, as well as highly avid CD8+ T-lymphocytes, leading to development of lymphopenia, to restore generation of adequate immune response in patients with SARS-CoV-2 infection with a severe course of the infectious process, increase the effectiveness of treating the disease caused by infection with SARS-CoV-2, reduce mortality in the severe course of COVID-19.

5 cl, 2 dwg, 1 tbl, 2 ex